Adding one year of adjuvant trastuzumab to chemotherapy treatment for HER2+ early-stage breast cancer patients incurred 22,845 US$ per QALY gained, which exceeded the cost-effective threshold of 1-time GDP per capita (i.e., 3,600 US$) by 6.3 times. Here, ERBB2 is linked to breast cancer.